JPRN-UMIN000003141RecruitingPhase 2
A randomised phase II trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in second-line treatment of advaneced or recurrent gastric cancer resistant to Docetaxel/Cisplatin/TS-1 (DCS) therapy - A randomized phase II study of CPT-11/CDDP versus CPT-11 in second-line treatment of advanced/recurrent gastric cancer after DCS chemotherapy
Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)0 sites80 target enrollmentStarted: February 6, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) With uncontrolled pleural effusion or ascites. (2) Active concomitant malignancy. (3) With infectious disease which needs treatment. (4) Uncontrolled medical conditions (e.g., congestive heart failure, ileus, interstitial pneumonia, pulmonary fibrosis, diabetes, interstitial pneumonia, pulmonary fibrosis, renal failure). (5) Watery stool (diarrhea). (6) With a history of mental disorder. (7) Pregnant or lactating women and women of child bearing potential not using contraception. (8) Drug hypersensitivity or severe drug allergy. (9) Inappropriate recruit to the study judged by an investigator in charge.
Investigators
Similar Trials
Completed
Phase 2
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
Active, not recruiting
Not Applicable
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATXEUCTR2006-006058-83-NLVU Medisch Centrum
Active, not recruiting
Phase 2
A phase II study for HER2 amplified advanced solid tumors (JUPITER trial)Solid tumorsHER2, solid tumorD009369JPRN-jRCT2031180150Ikeda Sadakatsu38
Not yet recruiting
Not Applicable
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
Completed
Phase 2
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18